Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Webinar: A Drug Repurposing Approach for Clinical Treatment of Triple-Negative Breast Cancer

Technology Opportunity Webinar, September 10th featuring William Reinhold

September 10, 2025 | 11:00 AM – 12:00 PM

Add to Outlook Calendar

If you are interested in obtaining a recording of the webinar, please reach out to joseph.conrad@nih.gov.

On September 10, 2025, NCI TTC hosted a free NIH technology webinar highlighting a novel, potential treatment for Triple-Negative Breast Cancer (TNBC). William Reinhold and his team at the NCI repurposed two separate therapeutic compounds ─ acetalax and bisacodyl (both previously used as laxatives) ─ into novel treatments for TNBC. Attend to learn more about this technology and opportunities to help develop and commercialize it.

About the Technology

The Problem:

TNBC is a highly invasive and hard to treat cancer. Responses to current treatment methods are usually short lived, followed by rapid relapse leading to visceral and brain metastasis. There is also no standard chemotherapy regimen for patients with relapsed/refractory TNBC. Therefore, there is a significant unmet need for new and effective treatment options to treat patients with TNBC. 

How the Solution Works:

  • Acetalax and bisacodyl show promising results in killing TNBC cells in patient-derived xenografts (PDX) cell lines and mouse models.
  • Acetalax and bisacodyl disrupt the activity of the protein transient receptor potential melastatin member 4 (TRPM4), which is over expressed in TNBC and several other cancers.  
  • Disruption of TRMP4 activity negatively affects its ability to regulate cancer cell migration, cytoskeleton maintenance and epithelial-mesenchymal transition (EMT).
  • Acetalax and bisacodyl's affect on TRMP4 disrupts the cancer cell membrane, causing oncosis (i.e., swelling and rupture), which kills cancer cells).

Competitive Advantages

  • Repurposed drugs provide:
    • reduced development costs
    • reduced development timelines
  • Bisacodyl may be eligible for expedited FDA approval based on current approval for different indication
  • Novel, potential TNBC treatment option compared to the current challenging to treat standard of care

Who should attend?

  • Business development professionals
  • Scientific and drug development professionals
  • Biotech/pharma/academia researchers
  • Investors and entrepreneurs

Why attend?

  • Assess co-developing the technology
  • Interact with the inventor, ask questions and provide feedback
  • Learn how to partner with the NIH facilitated by the NCI Technology Transfer Center

If you are interested in learning more about how to co-develop and/or license this technology, please contact Michael.Salgaller@nih.gov.
 

 

Email